Dossier assessment
Serplulimab (oesophageal squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Serplulimab (oesophageal squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Serplulimab (oesophageal squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma that cannot be treated with curative intent
- Patients whose tumours have a combined positive score (CPS)≥5 and also a tumour cell programmed cell death-ligand 1 (PD-L1) expression of ≥1%, or whose tumours have a CPS≥10 regardless of tumour cell PD-L1 expression; first-line treatment: added benefit not proven
- Patients whose tumours have a CPS between ≥5 and <10 and also no tumour cell PD-L1 expression of ≥1%; first-line treatment: added benefit not proven
Project details
- Project no.
- A26-90
- Commission
- Commission awarded on 23.06.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-90